Pneumologie 2017; 71(S 01): S1-S125
DOI: 10.1055/s-0037-1598379
Posterbegehung – Sektion Klinische Pneumologie
Asthma bronchiale – Stephanie Korn/Mainz, Christian Geßner/Leipzig
Georg Thieme Verlag KG Stuttgart · New York

Efficacy of tiotropium in patients aged 6 – 17 years with severe symptomatic asthma

Authors

  • E Hamelmann

    1   Department of Pediatrics, Evangelisches Krankenhaus Bielefeld and Allergy Center of the Ruhr University Bochum

  • SJ Szefler

    2   Department of Pediatrics, Children's Hospital Colorado and the University of Colorado School of Medicine

  • JA Bernstein

    3   Uc Allergy Clinical Research Center, University of Cincinnati College of Medicine

  • K Murphy

    4   Boys Town National Research Hospital, Boys Town Ne

  • G El Azzi

    5   Boehringer Ingelheim Pharma GmbH & Co. KG

  • M Engel

    5   Boehringer Ingelheim Pharma GmbH & Co. KG

  • P Moroni-Zentgraf

    5   Boehringer Ingelheim Pharma GmbH & Co. KG

  • R Sigmund

    5   Boehringer Ingelheim Pharma GmbH & Co. KG
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
23. Februar 2017 (online)

Auch verfügbar auf
 
 

    Purpose:

    We studied tiotropium Respimat® (tioR) add-on to ICS plus other controller medications in 6 – 17 year-olds with severe symptomatic asthma.

    Methods:

    Pooled analysis was performed of two 12-week studies comparing tioR 2.5 µg (2 puffs, 1.25 µg) and 5 µg (2 puffs, 2.5 µg) with placebo Respimat® (VivaTinA-asthma, NCT01634152, 6 – 11 year-olds, and PensieTinA-asthma, NCT01277523, 12 – 17 year-olds). The primary endpoint was peak FEV1(0 – 3h) change from baseline at 12 weeks; secondary endpoints included trough FEV1, ACQ, rescue medication use and exacerbations.

    Results:

    792 subjects were randomized. TioR improved peak FEV1(0 – 3h) versus placebo in the pooled analysis: tioR 2.5 µg 74 mL (95% CI 8, 140; P= 0.027), tioR 5 µg 117 mL (95% CI 51, 183, P= 0.0005). Separate study data: 6 – 11 year-olds tioR 2.5 µg 35 mL (95% CI -28, 99; P= 0.272), tioR 5 µg 139 mL (95% CI 75, 203, P< 0.0001); 12 – 17 year-olds tioR 2.5 µg 111 mL (95% CI 2, 220; P= 0.046), tioR 5 µg 90 mL (95% CI -19, 198, P= 0.104). Trough FEV1 versus placebo: pooled analysis tioR 2.5 µg 64 mL (95% CI -3, 132; P= 0.062), tioR 5 µg 71 mL (95% CI 3, 139, P= 0.040); 6 – 11 year-olds tioR 2.5 µg 18 mL (95% CI -48, 85; P= 0.590), tioR 5 µg 87 mL (95% CI 19, 154, P= 0.012); 12 – 17 year-olds tioR 2.5 µg 115 mL (95% CI -0.0, 231; P= 0.051), tioR 5 µg 54 mL (95% CI -61, 168, P= 0.361). In the pooled analysis, time to first exacerbation was significantly longer with tioR than placebo (tioR 2.5 µg P= 0.009, tioR 5 µg P= 0.029). Other secondary endpoints were not significantly different between groups. Adverse events were similar between groups.

    Conclusions:

    In the pooled analysis, tiotropium Respimat® add-on to ICS plus controller medication improved lung function and time to first exacerbation compared with placebo in 6 – 17 year-olds with severe symptomatic asthma.

    Clinical implications:

    Adding tiotropium Respimat® to existing controller medication may improve lung function and reduce exacerbations in children with severe symptomatic asthma.

    Content already presented at CHEST congress 2016


     

    Die Autoren geben an, dass kein Interessenkonflikt besteht.